FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379513010> ?p ?o ?g. }

• W4379513010 endingPage "77" @default.
• W4379513010 startingPage "77.2" @default.
• W4379513010 abstract "Background Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. Current treatments are empirical, partially effective, expose to a risk of side effects and a high rate of relapse upon discontinuation. DM muscular histology is characterized by lesions of perifascicular fibers consisting of atrophy, overexpression of type I interferon-dependent genes and mitochondrial dysfunctions of unknown origin [1]. Objectives The objective of the study was to identify innovative therapeutic strategies for DM, based on the identification of the molecular pathways that underlie perifascicular fibers lesions and the repositioning of drugs already approved in humans. Methods To reveal the molecular pathways underlying DM perifascicular fibers lesions, perifascicular and endofascicular fibers from 19 patients with recent and untreated myositis (DM, other myositis) or without myopathy were microdissected by laser, their transcriptome was established by RNA sequencing and analyzed by bioinformatic methods. To identify innovative therapeutic strategies based both on DM pathophysiological mechanisms and on existing drugs, the transcriptomic signature specific to DM perifascicular fibers obtained by microdissection experiments was used for a drug repositioning analysis as described by Karatzas et al. [2]. To validate the predications obtained, the effect of drug candidates already used in humans was tested in in vitro and in vivo preclinical models: in 1) cultured human muscle cells treated with IFN-I and in 2) a mouse model of myositis experimentally induced by immunization against skeletal muscle fast-type C protein. Results Transcriptomic analysis of patient’s muscle fibers combined with topographic information (perifascicular VS endofascicular localization) revealed that a proteasome deregulation predominant in the perifascicular fibers is a hallmark of DM. The integration of 3 computer databases of drug repositioning allowed the identification of 9 molecules predicted by at least 2 bases to reverse the pathological signature of the perifascicular fibers of patients with DM. The drug with the highest therapeutic potential was a proteasome inhibitor (Ixazomib). A second proteasome inhibitor (MG-132) was also identified. 2 drugs already used for DM (prednisolone and a JAK inhibitor) was identified with a lower therapeutic score. In the cellular model (human myotubes treated with IFN-I) ixazomib and bortezomib reversed the atrophy and the pathological signature of DM perifascicular fibers identified in the microdissection experiments. In the mouse model of myositis, ixazomib and bortezomib restored muscle strength, decreased blood creatine kinase, and reversed the atrophy of muscle fibers. Conclusion Proteasome inhibition could be a new effective therapeutic strategy for DM. References [1]Meyer et al. 2017. IFN-β-Induced Reactive Oxygen Species and Mitochondrial Damage Contribute to Muscle Impairment and Inflammation Maintenance in Dermatomyositis. Acta Neuropathol. 134 (4): 655-66. [2]Karatzas et al. 2019. An Application of Computational Drug Repurposing Based on Transcriptomic Signatures. Methods Mol Biol 1903, 149-177. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379513010 created "2023-06-07" @default.
• W4379513010 creator A5000028240 @default.
• W4379513010 creator A5002590489 @default.
• W4379513010 creator A5004310875 @default.
• W4379513010 creator A5005595984 @default.
• W4379513010 creator A5029466909 @default.
• W4379513010 creator A5037847620 @default.
• W4379513010 creator A5044165958 @default.
• W4379513010 creator A5054531972 @default.
• W4379513010 creator A5056295276 @default.
• W4379513010 creator A5076439643 @default.
• W4379513010 creator A5085246786 @default.
• W4379513010 date "2023-05-30" @default.
• W4379513010 modified "2023-10-16" @default.
• W4379513010 title "OP0117 PROTEASOME INHIBITION AS A NEW TREATMENT FOR DERMATOMYOSITIS: RESULTS OF A DRUG REPURPOSING ANALYSIS BASED ON THE TRANSCRIPTOMIC SIGNATURE OF PATIENTS’ PERIFASCICULAR FIBERS VALIDATED IN PRE-CLINICAL MODELS" @default.
• W4379513010 doi "https://doi.org/10.1136/annrheumdis-2023-eular.6464" @default.
• W4379513010 hasPublicationYear "2023" @default.
• W4379513010 type Work @default.
• W4379513010 citedByCount "0" @default.
• W4379513010 crossrefType "journal-article" @default.
• W4379513010 hasAuthorship W4379513010A5000028240 @default.
• W4379513010 hasAuthorship W4379513010A5002590489 @default.
• W4379513010 hasAuthorship W4379513010A5004310875 @default.
• W4379513010 hasAuthorship W4379513010A5005595984 @default.
• W4379513010 hasAuthorship W4379513010A5029466909 @default.
• W4379513010 hasAuthorship W4379513010A5037847620 @default.
• W4379513010 hasAuthorship W4379513010A5044165958 @default.
• W4379513010 hasAuthorship W4379513010A5054531972 @default.
• W4379513010 hasAuthorship W4379513010A5056295276 @default.
• W4379513010 hasAuthorship W4379513010A5076439643 @default.
• W4379513010 hasAuthorship W4379513010A5085246786 @default.
• W4379513010 hasBestOaLocation W43795130101 @default.
• W4379513010 hasConcept C103637391 @default.
• W4379513010 hasConcept C104317684 @default.
• W4379513010 hasConcept C125965507 @default.
• W4379513010 hasConcept C142724271 @default.
• W4379513010 hasConcept C150194340 @default.
• W4379513010 hasConcept C162317418 @default.
• W4379513010 hasConcept C207001950 @default.
• W4379513010 hasConcept C2778751314 @default.
• W4379513010 hasConcept C2780035454 @default.
• W4379513010 hasConcept C2781232998 @default.
• W4379513010 hasConcept C54355233 @default.
• W4379513010 hasConcept C60644358 @default.
• W4379513010 hasConcept C70721500 @default.
• W4379513010 hasConcept C71924100 @default.
• W4379513010 hasConcept C86803240 @default.
• W4379513010 hasConcept C98274493 @default.
• W4379513010 hasConceptScore W4379513010C103637391 @default.
• W4379513010 hasConceptScore W4379513010C104317684 @default.
• W4379513010 hasConceptScore W4379513010C125965507 @default.
• W4379513010 hasConceptScore W4379513010C142724271 @default.
• W4379513010 hasConceptScore W4379513010C150194340 @default.
• W4379513010 hasConceptScore W4379513010C162317418 @default.
• W4379513010 hasConceptScore W4379513010C207001950 @default.
• W4379513010 hasConceptScore W4379513010C2778751314 @default.
• W4379513010 hasConceptScore W4379513010C2780035454 @default.
• W4379513010 hasConceptScore W4379513010C2781232998 @default.
• W4379513010 hasConceptScore W4379513010C54355233 @default.
• W4379513010 hasConceptScore W4379513010C60644358 @default.
• W4379513010 hasConceptScore W4379513010C70721500 @default.
• W4379513010 hasConceptScore W4379513010C71924100 @default.
• W4379513010 hasConceptScore W4379513010C86803240 @default.
• W4379513010 hasConceptScore W4379513010C98274493 @default.
• W4379513010 hasIssue "Suppl 1" @default.
• W4379513010 hasLocation W43795130101 @default.
• W4379513010 hasOpenAccess W4379513010 @default.
• W4379513010 hasPrimaryLocation W43795130101 @default.
• W4379513010 hasRelatedWork W1520959350 @default.
• W4379513010 hasRelatedWork W1649471366 @default.
• W4379513010 hasRelatedWork W2037927825 @default.
• W4379513010 hasRelatedWork W2053589691 @default.
• W4379513010 hasRelatedWork W2148679377 @default.
• W4379513010 hasRelatedWork W2398816925 @default.
• W4379513010 hasRelatedWork W2894389059 @default.
• W4379513010 hasRelatedWork W3095610875 @default.
• W4379513010 hasRelatedWork W3107337972 @default.
• W4379513010 hasRelatedWork W4206291286 @default.
• W4379513010 hasVolume "82" @default.
• W4379513010 isParatext "false" @default.
• W4379513010 isRetracted "false" @default.
• W4379513010 workType "article" @default.